ArticleFrontiers in cell and developmental biology2023

Circulating IL-6 and not its circulating signaling components sIL-6R and sgp130 demonstrate clinical significance in NSCLC patients treated with immune checkpoint inhibitors.

Yoshiro Nakahara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.